Valneva’s Q1 Revenue Takes a 40% Hit From Restructuring, but Lyme Vaccine and Shigella Data Loom Large

Valneva's Q1 2026 revenue fell nearly 40% to €30.9M, net loss widened to €32.1M, but Lyme vaccine LB6V with >70% efficacy in phase 3 offers hope. Stock down ~34% YTD.

Valneva’s pipeline provided a much-needed bright spot during a quarter marked by sliding revenue and a deepening net loss. The biotechnology company and its partner Pfizer are preparing regulatory submissions for the experimental Lyme disease vaccine LB6V after phase 3 data showed efficacy above 70% in people aged five and older, with no safety concerns flagged. The achievement stands in stark contrast to Valneva’s first quarter financial results, where the top line fell sharply.

Revenue for the three months ended March 2026 came in at €30.9 million, down nearly 40% from the €49.2 million recorded in the same period a year earlier. The per-share loss of $0.42 far exceeded the $0.18 deficit analysts had penciled in. Operating losses widened to €23.7 million from €6.0 million, and the net loss ballooned to €32.1 million. Sales of Valneva’s three core vaccines were mixed: IXIARO/JESPECT for Japanese encephalitis generated €20.2 million, DUKORAL for cholera and travel diarrhea contributed €8.6 million, while the Chikungunya vaccine IXCHIQ added only €1.6 million.

A deliberate strategic retreat from the distribution of third-party vaccines played a major role in the revenue slide. Revenue from that business collapsed to just €0.1 million from €5.8 million in the prior-year quarter. Management aims to reduce third-party product sales to less than 5% of total turnover by the end of 2026 or 2027, a move designed to improve overall margins. A parallel restructuring program targets a 25% to 35% reduction in operating costs relative to 2025 and will shrink the workforce by 10% to 15%.

To shore up finances, Valneva ended March with €105.3 million in cash and then added another €84 million through a capital raise in April. Even so, the company lowered its full-year 2026 guidance to between €145 million and €160 million in total revenue. That caution reflects the ongoing transition away from lower-margin products and the uncertainty surrounding the timing of new vaccine launches.

On the stock market, the narrative remains one of deep discounting. Shares closed at €2.54 on Wednesday, a level roughly 35% below the 200-day moving average and representing a decline of about 34% since the start of the year. The stock has also fallen by nearly half from its 52-week high, underscoring investor anxiety over execution risks and the long road to profitability.

Operationally, Valneva is pushing ahead with other pipeline candidates. Phase 2 studies for the Shigella vaccine candidate S4V2 are ongoing, with first results expected by mid-2026 — a key catalyst investors will watch closely. In a separate development, Brazil’s health regulator has given the green light for local production of the Chikungunya vaccine, potentially opening a significant emerging market channel.

For the rest of the year, the company’s near-term trajectory hinges on two milestones: Pfizer’s filing of the Lyme vaccine with regulatory agencies and the Shigella data readout. Together, they offer a counterbalance to the financial squeeze of restructuring, even if the path to a full recovery in the share price remains fraught.